IO Biotech News

News

Ticker

IOBT

ISIN

US4497781090

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

IO Biotech Eulerpool News

IO Biotech Stock News

IO Biotech is being monitored by journalists and investors worldwide. We gather the latest IO Biotech news here.

February 13·
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 6·
ChartMill
Curious about the stocks that are showing activity after the closing bell on Friday?
January 26·
Benzinga
IO Biotech shares are trading lower after Piper Sandler downgraded the stock from Overweight to Neutral and cut its price target from $3 to $0.5.
January 21·
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 21·
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 21·
Yahoo
IO Biotech Announces Exploration of Strategic Alternatives
January 20·
Yahoo
Moderna cancer vaccine holds up; IO Biotech considers a sale
December 15·
Yahoo
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
November 27·
SeekingAlpha
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3
November 14·
Yahoo
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
November 7·
Yahoo
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 20·
Yahoo
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
September 30·
Yahoo
IO Biotech Faces Setback as FDA Opposes Cylembio BLA Submission, Morgan Stanley Says
September 29·
Benzinga
Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings
September 23·
Benzinga
IO Biotech To Present Phase 3 And Final Phase 2 Trial Results For IO102-IO103 Cancer Vaccine Plus Pembrolizumab At 2025 ESMO Congress
September 9·
SeekingAlpha
IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
August 26·
Yahoo
H.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14
August 15·
Benzinga
IO Biotech shares are trading higher following the release of its Q2 financial results.
August 12·
SeekingAlpha
IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma
August 11·
Yahoo
IO Biotech to pursue cancer vaccine approval despite Phase III miss

IO Biotech Stock Press Releases

IO Biotech regularly publishes news on the company's website that are relevant for investors.

IO Biotech News 2026

This page contains all current news, analysis and press releases for IO Biotech stock (IOBT, ISIN: US4497781090). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at IO Biotech.

IO Biotech Stock

IO Biotech IO Biotech Inc, based in Copenhagen, Denmark, operates in the Health Care sector, specializing in Biotechnology. The company develops immune modulating cancer therapies using its T-win technology platform, focusing on disrupting tumor-induced immunosuppression. Its lead product candidate, IO102-IO103, targets immunosuppressive proteins like IDO and PD-L1. Founded as a spin-off from the National Cancer Center Immune Therapy at Herlev University Hospital, IO Biotech has 57 employees and is listed on the stock exchange since November 5, 2021.